Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

ConclusionsSamalizumab had a good safety profile and treatment was associated with reduced tumor burden in a majority of patients with advanced CLL. These preliminary positive results support further development of samalizumab as an immune checkpoint inhibitor.Trial registrationClinicalTrials.gov,NCT00648739 registered April 1, 2008.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research